ArticleClinical, cosmetic and investigational dermatology2026
Associations of Total IgE, Eosinophils, and IL-5 with SCORAD-Defined Severity in High-IgE Atopic Dermatitis: A Retrospective Exploratory Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is characterized by marked immune heterogeneity, and high-IgE AD is commonly associated with Th2-skewed inflammation and greater disease burden. However, the relationships between downstream Th2-related peripheral blood markers and multidimensional disease severity in high-IgE AD remain incompletely understood. Methods: This single-center retrospective exploratory study included adult patients with AD diagnosed between June 2023 and June 2025. Among 140 eligible patients with complete core data, 92 patients with high-IgE AD, defined as baseline serum total IgE ≥100 IU/mL, were included in the primary analysis. Patients were stratified according to SCORAD scores. Associations of total IgE, eosinophil (EOS) count, and IL-5 with SCORAD, EASI, NRS pruritus score, and DLQI were analyzed. Results: Total IgE, EOS count, and IL-5 levels were significantly higher in patients with SCORAD-defined moderate-to-severe high-IgE AD than in those with mild disease. Total IgE showed consistent positive correlations with SCORAD, EASI, NRS pruritus score, and DLQI, and remained statistically associated with SCORAD after multivariable adjustment. In exploratory logistic analysis, the IgE-EOS-log10(IL-5) combination showed moderate apparent discrimination for SCORAD-defined severity stratification, with an apparent AUC of 0.745 and a bootstrap-corrected AUC of 0.717. However, the combined marker set was not statistically superior to total IgE alone by the DeLong test. Conclusion: Among the evaluated biomarkers, total IgE showed the strongest and most consistent association with multidimensional disease severity in adult high-IgE AD. Although the IgE-EOS-log10(IL-5) combination provided exploratory adjunctive information for SCORAD-defined severity stratification, it did not show statistically significant added value over total IgE alone. External validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.